Hepatology : Current therapeutic approaches in childhood chronic hepatitis B infection: A multicenter study

Basit Öğe Kaydı
dc.authorid0000-0002-5299-9480en_US
dc.authorid0000-0002-8390-5109en_US
dc.authorid0000-0001-8484-1285en_US
dc.authorid0000-0002-3133-9846en_US
dc.authorid0000-0003-3151-3741en_US
dc.authorid0000-0002-8113-286Xen_US
dc.contributor.authorDikici, Bünyamin
dc.contributor.authorÖzgenç, Funda
dc.contributor.authorKalaycı, Ayhan Gazi
dc.contributor.authorTargan, Şeref
dc.contributor.authorÖzkan, Tanju
dc.contributor.authorSelimoğlu, Ayşe
dc.contributor.authorDoğancı, Tumay
dc.contributor.authorKansu, Aydan
dc.contributor.authorTosun, Selma
dc.contributor.authorArslan, Nur
dc.contributor.authorKasırga, Erhun
dc.contributor.authorBoşnak, Mehmet
dc.contributor.authorHaspolat, Yusuf Kenan
dc.contributor.authorBüyükgebiz, Benal
dc.contributor.authorAydoğdu, Sema
dc.contributor.authorGirgin, Nurten
dc.contributor.authorYağcı, Raşit Vural
dc.date.accessioned2021-12-03T13:16:13Z
dc.date.available2021-12-03T13:16:13Z
dc.date.issued2004en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground and aim: The aim of the present study was to compare the therapeutic efficacy of three different regimens in childhood chronic hepatitis B (CHB) infection. Methods: A total of 182 children with CHB infection were prospectively allocated to three random groups. Sixty-two patients in the first group received high-dose interferon (IFN)-alpha 2b (10 MU/m2) thrice/weekly alone for 6 months. In the second (n = 60) and third groups (n = 60), IFN-alpha was used for 6 months (5 MU/m2) thrice/weekly in combination with lamivudine (LAM) (4 mg/kg, maximum 100 mg/day) for 12 months. Lamivudine was started simultaneously with IFN in the second group, while it was started 2 months prior to IFN injections in the third group. Results: The initial mean alanine aminotransferase (ALT) values for the first, second and third groups were 109 +/- 93 IU/L, 101 +/- 64 IU/L and 92 +/- 42 IU/L, respectively (P > 0.05). At the end of the therapy, ALT values decreased to 82 +/- 111 IU/L, 38 +/- 41 IU/L and 29 +/- 16 IU/L in groups 1, 2 and 3, respectively. The mean ALT value of the first group was significantly different to the second and third groups (P = 0.046 and P = 0.002, respectively) at the end of the therapy and these differences were found to be sustained after 18 months. However, results in the second and third groups were similar (P > 0.05). There were no significant differences in HBeAg clearance and anti-HBe seroconversion at the initial stage, 12 months and 18 months between the three groups (P > 0.05). Hepatitis B virus (HBV) DNA clearance in the first group was different from the second and third groups, while the second and third groups had similar HBV DNA clearance ratios at 12 and 18 months. No significant difference was found in the complete response (normalization of ALT, clearance of HBV DNA and seroconversion of anti HBe) ratios of all groups (at 12 months: 28.8, 45.5, 35.8% and at 18 months 33.3, 49 and 34% in groups 1, 2 and 3, respectively, P > 0.05). Conclusions: Although the ALT normalization and HBV DNA clearance ratios of IFN plus LAM combination groups were better than the high-dose IFN-alpha monotherapy group, no significant difference was found in the complete response ratios of all three groups.en_US
dc.identifier.citationDikici, B., Özgenç, F., Kalaycı, A. G., Targan, Ş., Özkan, T., Selimoğlu, A. ve diğerleri. (2004). Hepatology : Current therapeutic approaches in childhood chronic hepatitis B infection: A multicenter study. Journal of Gastroenterology and Hepatology, 19(2), 127-133.en_US
dc.identifier.doi10.1111/j.1440-1746.2004.03209.x
dc.identifier.endpage133en_US
dc.identifier.issn1440-1746
dc.identifier.issue2en_US
dc.identifier.pmid14731120
dc.identifier.scopus2-s2.0-10744221461
dc.identifier.scopusqualityQ1
dc.identifier.startpage127en_US
dc.identifier.urihttps://hdl.handle.net/11468/8357
dc.identifier.volume19en_US
dc.identifier.wosWOS:000189072800002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDikici, Bünyamin
dc.institutionauthorBoşnak, Mehmet
dc.institutionauthorHaspolat, Yusuf Kenan
dc.language.isoenen_US
dc.publisherJournal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australiaen_US
dc.relation.ispartofJournal of Gastroenterology and Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChildrenen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectInterferon-αen_US
dc.subjectLamivudineen_US
dc.subjectTherapyen_US
dc.titleHepatology : Current therapeutic approaches in childhood chronic hepatitis B infection: A multicenter studyen_US
dc.titleHepatology : Current therapeutic approaches in childhood chronic hepatitis B infection: A multicenter study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Current therapeutic approaches in childhood chronic hepatitis B.pdf
Boyut:
106.07 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu